Does SelectHealth Cover Wegovy?
The verdict
Conditional on most plans
SelectHealth (Intermountain Health) covers Wegovy for weight management with prior authorization on commercial plans that include the anti-obesity benefit, with published criteria: BMI 30 or higher, or BMI 27 or higher with a weight-related comorbidity, plus documented prior weight-loss attempts. Not every SelectHealth plan includes the benefit — confirm plan inclusion before submitting PA. Medicare covers only the cardiovascular risk reduction indication.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with SelectHealth using your member ID.
Key facts
SelectHealth publishes PA criteria for Wegovy weight-loss coverage: BMI 30 or higher (or 27 or higher with a comorbidity) plus documented prior weight-loss attempts — a more concrete framework than many regional plans that do not publish drug-level detail.
SelectHealth, prior authorization criteria for anti-obesity agents
SelectHealth and Regence overlap in Utah and Idaho — but Regence does not publish Wegovy drug-level detail, while SelectHealth has published its BMI and prior-attempt PA criteria, differentiating the two plans' transparency for patients.
SelectHealth and Regence member formularies
Wegovy is FDA-approved for chronic weight management (BMI 30+, or 27+ with a weight-related comorbidity) and for cardiovascular risk reduction in adults with established CVD — it is a weight-loss and CV drug, not a diabetes drug.
FDA, Wegovy (semaglutide) prescribing information
Medicare vs. commercial coverage
Whether SelectHealth covers Wegovy depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Medicare Part D cannot cover Wegovy for weight loss by federal statute. For SelectHealth Medicare members with established cardiovascular disease who are overweight or obese, the cardiovascular risk reduction indication is coverable under Part D with prior authorization. The $2,100 beneficiary OOP cap applies in 2026. The Medicare GLP-1 Bridge (launching July 1, 2026, through December 31, 2027) provides weight-loss access to Wegovy at a fixed $50 per month copay outside Part D — this does not count toward the deductible, TrOOP, or the $2,100 cap. Bridge eligibility requires provider attestation: BMI 35 or higher; or BMI 30 or higher with heart failure, uncontrolled hypertension, or CKD; or BMI 27 or higher with prediabetes, prior MI, prior stroke, or symptomatic PAD. Members already receiving a Part D-covered GLP-1 are ineligible. Medicare beneficiaries cannot use the NovoCare savings card.
Commercial / Employer
Group & marketplace plans
SelectHealth is Intermountain Health's plan, serving Utah, Idaho, Nevada, and Colorado. It provides slightly more published PA structure for Wegovy than many not-publicly-published regional plans: commercial plans that include the weight-loss benefit cover Wegovy with prior authorization requiring BMI 30 or higher (or 27 or higher with a comorbidity) and documented prior weight-loss attempts. Not every SelectHealth plan includes the anti-obesity drug benefit — the plan must specifically include it. ACA/individual plans generally exclude Wegovy for weight loss. Medicaid coverage is state-dependent across UT/ID/NV; non-weight-loss FDA indications are covered under applicable Medicaid programs. Per-plan tier is not publicly published; verify specific cost-share with SelectHealth. If the benefit is absent from the plan, this is a benefit exclusion — prior-authorization paperwork will not override it.
The 5 boxes you must tick to get approved
Commercial plans that will consider Wegovy require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
0 of 5 requirements selected. Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Wegovy actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
$1,349 per month (Novo Nordisk published list price for a 28-day supply)
List price with no coverage — before any manufacturer savings card.
With coverage
Commercial cost-share where the plan includes the benefit: not publicly published per-plan; varies by tier. NovoCare Wegovy Savings Offer: commercially insured SelectHealth members whose plan covers Wegovy may pay as little as $25 per month (max savings $100 per 28-day supply). ACA/individual members generally excluded from weight-loss coverage. Medicare CV indication: Part D cost-share depends on tier and benefit phase; $2,100 OOP cap 2026. Medicare Bridge (weight loss, from 7/1/2026): fixed $50 per month outside Part D.
Typical monthly copay once prior authorization is approved.
Bridge program
NovoCare self-pay program: approximately $199 per month for starting doses (0.25/0.5 mg, first two fills through December 31, 2026), then approximately $349 per month for standard doses. Not available to Medicare or Medicaid beneficiaries. From January 1, 2027, Novo Nordisk has announced a list-price reduction to approximately $675 per month; the IRA-negotiated Maximum Fair Price of $274 per 30-day supply also takes effect January 1, 2027.
Reduced copay through the assistance program, where eligible.
All figures are estimates. Actual cost-share varies by plan tier and pharmacy. Confirm with SelectHealth member services or the plan drug-lookup tool.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Confirm whether your SelectHealth plan includes the anti-obesity benefit
Not every SelectHealth plan includes anti-obesity drug coverage. Before any PA paperwork, confirm with SelectHealth member services or your HR department that the weight-loss drug benefit is included in your specific plan. This one step prevents wasted effort on a PA for an excluded benefit.
- 2
Prepare your BMI and prior weight-loss attempt documentation
SelectHealth requires BMI documentation (30 or higher, or 27 or higher with a comorbidity) and documented prior weight-loss attempts. Gather records of previous weight-loss efforts — dietary programs, medical interventions, or behavioral programs — before your prescriber submits the PA.
- 3
Ask your prescriber about the CV indication or Bridge eligibility if applicable
If you have established cardiovascular disease and are overweight or obese, ask your provider whether the cardiovascular risk reduction indication provides a separate coverage path. Medicare SelectHealth members should ask about GLP-1 Bridge eligibility (launching July 1, 2026, $50/month outside Part D).
Options if SelectHealth won't cover Wegovy
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
SelectHealth anti-obesity benefit (where plan includes it)
For SelectHealth commercial members whose plan includes the weight-loss benefit, the PA process uses published criteria: BMI 30 or higher (or 27 or higher with comorbidity) and documented prior weight-loss attempts. The approval path is predictable when the benefit is in the plan.
Cardiovascular indication (Medicare Part D or commercial)
Wegovy is FDA-approved for cardiovascular risk reduction in adults with established CVD who are overweight or obese. This indication may be coverable under Medicare Part D or certain SelectHealth commercial plans with prior authorization, independent of the weight-loss benefit.
Medicare GLP-1 Bridge
Launching July 1, 2026, the Bridge provides eligible Medicare beneficiaries weight-loss access to Wegovy at $50 per month through December 31, 2027, outside Part D. Eligibility criteria apply; members already on a Part D-covered GLP-1 are ineligible.
Compounded semaglutide
Compounded semaglutide, available through licensed telehealth platforms, does not require insurance prior authorization. Starting from $49 per month. Compounded semaglutide is not the same medication as Wegovy and has not been approved by the FDA.
These options are listed for information only — your own clinician decides what is appropriate for you.
Frequently Asked Questions
SelectHealth covers Wegovy with prior authorization on commercial plans that include the anti-obesity benefit — the criteria are BMI 30 or higher (or 27 or higher with a comorbidity) plus documented prior weight-loss attempts. The key condition is that your specific plan includes the benefit; not every SelectHealth plan does. Confirm the benefit is in your plan before initiating PA. ACA/individual plans generally exclude it. Medicare covers only the CV indication.
Both SelectHealth and Regence serve overlapping territory in Utah and Idaho. SelectHealth has published PA criteria for Wegovy (BMI 30 or higher, or 27 or higher with comorbidity, documented prior weight-loss attempts) — a more concrete conditional-covered framework than Regence, whose Wegovy detail is not publicly published. Patients comparing the two plans should note that SelectHealth's PA structure gives a clearer roadmap when the benefit is in the plan, while Regence members must verify through the drug-lookup tool without a published starting point.
SelectHealth requires documentation of prior weight-loss attempts as part of its Wegovy PA criteria. The specific documentation requirements are not published in full at the drug level — your prescriber should confirm what records are needed (dietary programs, behavioral interventions, prior medications) before submitting the PA to SelectHealth. The prior-attempt requirement is distinct from plans that only need BMI documentation and current enrollment in a lifestyle program.
Commercially insured SelectHealth members whose plan covers Wegovy may use the NovoCare Wegovy Savings Offer (as little as $25 per month, max savings $100 per 28-day supply). The card is not available to Medicare or Medicaid beneficiaries due to federal anti-kickback rules. ACA exchange and state-employee plans are not treated as government programs for this offer. If your SelectHealth plan excludes the anti-obesity benefit, the savings card cannot be applied to a non-covered use at standard retail.
If the anti-obesity benefit is excluded from your SelectHealth plan, this is a benefit exclusion — not a medical-necessity denial. A prior-authorization appeal will not succeed because the drug category is simply not in the covered benefit. The practical paths are: asking your employer whether the benefit can be added at the next renewal; confirming whether your plan is self-funded (which may allow more flexibility); or exploring self-pay options including the NovoCare self-pay program (approximately $349/month for standard doses) or compounded semaglutide through a telehealth provider.
Related Articles
Does BCBS North Carolina Cover Wegovy? 2026 | Curex
BCBS North Carolina: NC State Health Plan dropped weight-loss GLP-1s in 2024; NC Medicaid removed obesity coverage October 2025. Verify your specific plan.
Read moreDoes BCBS of Arizona Cover Wegovy? 2026 Guide | Curex
BCBS of Arizona covers Wegovy only where your employer opted in; formulary not published. Verify via drug-lookup and confirm with HR first.
Read moreDoes Blue Cross Blue Shield Cover Wegovy? 2026 | Curex
BCBS is 33+ independent affiliates — no single Wegovy answer. Trend favors exclusion in 2025-2026. Find your affiliate and verify your formulary.
Read moreDoes Blue Cross Blue Shield of Illinois Cover Wegovy? | Curex
BCBS Illinois (HCSC) covers Wegovy only where your employer opts in. ACA plans exclude it. Formulary not public — verify on your plan's drug-lookup tool.
Read moreDoes BCBS Alabama Cover Wegovy? 2026 Guide | Curex
BCBS Alabama Wegovy coverage is employer-dependent and unpublished. Alabama Medicaid excludes obesity GLP-1s. How to verify your specific plan.
Read moreDoes Humana Cover Wegovy? Medicare Bridge Guide | Curex
Humana Part D cannot cover Wegovy for weight loss by statute. Covers it for CV risk reduction with PA. Humana runs the GLP-1 Bridge: $50/mo from July 2026.
Read moreWhether or not SelectHealth covers Wegovy, there's a path that skips insurance
You just saw how tangled Wegovy coverage can get — auto-rejections, prior authorization, and high cash prices. Curex compounded semaglutide: $199/month equivalent prepaid annually ($2,388 upfront), or $299/month paid monthly. Compounded tirzepatide: $299/month equivalent prepaid annually ($3,588 upfront), or $399/month paid monthly. Commercial rates as of 2026-10-12; compounded products are not FDA-approved and clinical eligibility must be assessed. Curex compounded medications are not the same as Wegovy. No insurance or prior authorization required; prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Wegovy and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with SelectHealth before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Wegovy and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.